Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo.

Clin Infect Dis. 2000 Jan V.30 N.1 P.19-24.

Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group.

Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Thomas C, Panzer H, Dismukes WE.

Source

Wayne State University, Detroit, MI 48201, USA. jsobel@intmed.wayne.edu    

Abstract

Management of candiduria is limited by the lack of information about its natural history and lack of data from controlled studies on the efficacy of treating it with antimycotic agents. We compared fungal eradication rates among 316 consecutive candiduric (asymptomatic or minimally symptomatic) hospitalized patients treated with fluconazole (200 mg) or placebo daily for 14 days. In an intent-to-treat analysis, candiduria cleared by day14 in79 (50%) of 159 receiving fluconazole and 46 (29%) of 157 receiving placebo (P<.001), with higher eradication rates among patients completing 14 days of therapy (P<.0001), including 33 (52%) of 64 catheterized and 42 (78%) of 54 noncatheterized patients. Pretreatment serum creatinine levels were inversely related to candiduria eradication. Fluconazole initially produced high eradication rates, but cultures at 2 weeks revealed similar candiduria rates among treated and untreated patients. Oral fluconazole was safe and effective for short-term eradication of candiduria, especially following catheter removal. Long-term eradication rates were disappointing and not associated with clinical benefit.

PDF

http://cid.oxfordjournals.org/content/30/1/19.full.pdf+html

Comment in

Clin Infect Dis. 2000 Jul;31(1):209-10.

PDF

http://cid.oxfordjournals.org/content/31/1/209.long